Long‐term disease‐free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third‐complementarity‐determining region‐specific probes

Kun‐Huei ‐H Yeh, Ming‐Tseh ‐T Lin, Jih‐Luh ‐L Tang, Chih‐Hsin ‐H Yang2, Woei Tsay, Yao‐Chang ‐C Chen

Research output: Contribution to journalArticle

Abstract

Primary plasma cell leukaemia (PPCL) is a rare form of plasma cell neoplasm. Treatments of PPCL have been most disappointing. A patient with PPCL received high‐dose melphalan plus total body irradiation and autologous bone marrow transplantation (ABMT). By using third‐complementarity‐determining region (CDRIII)‐specific probes, minimal residual disease (MRD) was detected in remission marrow, collected 1 month before ABMT. MRD was no longer detected by CDRIII‐specific probes 6, 19 and 26 months after transplantation. The patient remained in complete remission up to 59 months after ABMT.

Original languageEnglish (US)
Pages (from-to)914-916
Number of pages3
JournalBritish journal of haematology
Volume89
Issue number4
DOIs
StatePublished - Apr 1995
Externally publishedYes

Keywords

  • ABMT
  • CDRIII
  • primary plasma cell leukaemia

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Long‐term disease‐free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third‐complementarity‐determining region‐specific probes'. Together they form a unique fingerprint.

  • Cite this